February 22, 2013 at 05:59 AM EST
Sihuan Granted SFDA Approval to Test New Diabetes Drug
Sihuan Pharma received permission from the SFDA to begin clinical trials of pinoxacin hydrochloride, a Category 1.1 drug. The drug is a DPP-4 inhibitor that is intended for type 2 diabetics. The Beijing-based company said it would start a Phase I trial in the first half of 2013. In January, Sihuan announced approval to begin clinical trials of another Category 1.1 drug, an innovative carbapenem antibiotic known as benapenum. So far, four of Sihuan’s Category 1 drugs have received approval for human testing. More details.... Stock Symbol: (HK: 0460) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here